### Contents

**Highlights of This Issue** 1219

**SPOTLIGHT ON CLINICAL RESPONSE**

1221  
**Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent**  
Siqing Fu, Aung Naing, Caroline Fu, Macus Tien Kuo, and Razelle Kurzrock

1226  
**REVIEW**  
**New Directions for Biologic Targets in Urothelial Carcinoma**  
Suzanne Richter and Srikala S. Sridhar

**THERAPEUTIC DISCOVERY**

1236  
**Antitumor Mechanisms of Targeting the PDK1 Pathway in Head and Neck Cancer**  
Neil E. Bhola, Maria L. Freillino, Sonali C. Joyce, Malabika Sen, Suji M. Thomas, Anirban Sahu, Andre Cassell, Ching-Shih Chen, and Jennifer R. Grandis

1247  
**IGF-1R/MDM2 Relationship Confers Enhanced Sensitivity to RITA in Ewing Sarcoma Cells**  
Giusy Di Conza, Marianna Buttarelli, Olimpia Monti, Marsha Pellegrino, Francesca Mancini, Alfredo Pontecorvi, Katia Scotlandi, and Fabiola Moretti

1257  
**Identification and Characterization of MEL-3, a Novel AR Antagonist That Suppresses Prostate Cancer Cell Growth**  
Christine Helsen, Arnaud Marchand, Patrick Chaltin, Sebastian Munck, Arnout Voet, Annemieke Verstuyf, and Frank Claessens

**PRECLINICAL DEVELOPMENT**

1269  
**Dibenzophenanthridines as Inhibitors of Glutaminase C and Cancer Cell Proliferation**  
William P. Katt, Sekar Ramachandran, Jon W. Erickson, and Richard A. Cerione

1279  
**An Antibody Fusion Protein for Cancer Immunotherapy Mimicking IL-15 trans-Presentation at the Tumor Site**  
Vanessa Kermer, Volker Baum, Nora Hornig, Roland E. Kontermann, and Dafne Müller

1289  
**STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression**  
Shinji Kohsaka, Lei Wang, Kazuhiro Yachi, Roshan Mahabir, Takuhito Narita, Tamio Itoh, Mishie Tanino, Taichi Kimura, Hiroshi Nishihara, and Shinya Tanaka

1300  
**Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions**  
Rona Ortenberg, Yair Sapir, Lee Raz, Liat Hershkovitz, Ayelet Ben Avr, Sivao Sapoznik, Iris Barshack, Camila Avivi, Yackov Berkun, Michal J. Besser, Tehila Ben-Moshe, Jacob Schachter, and Gal Marked

1311  
**HDL Mimetics Inhibit Tumor Development in Both Induced and Spontaneous Mouse Models of Colon Cancer**  

1320  
**Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells**  
Sheng Tai, Yin Sun, Nan Liu, Boxiao Ding, Elaine Hsia, Sunita Bhuta, Ryan K. Thor, Robert Damoiseaux, Chaozhao Liang, and Jiaoti Huang

1332  
**Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs**  
Ali R. Jazirehi and James S. Economou

1342  
**Predominance of mTORC1 over mTORC2 in the Regulation of Proliferation of Ovarian Cancer Cells: Therapeutic Implications**  
Juan Carlos Montero, Xi Chen, Alberto Ocaña, and Atanasio Pandiella

---

The Cancer Drug Development Journal: From Concept to Clinic  iii  www.aacrjournals.org

Downloaded from mct.aacrjournals.org on June 21, 2017. © 2012 American Association for Cancer Research.
The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models

Effect of Small-Molecule–Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody
Kelly Davis Orcutt, John J. Rhoden, Benjamin Ruiz-Yi, John V. Frangioni, and K. Dane Wittrup

Glycolytic Inhibition Alters Anaplastic Thyroid Carcinoma Tumor Metabolism and Improves Response to Conventional Chemotherapy and Radiation
Vlad C. Sandulache, Heath D. Skinner, Yuan Wang, Yunyun Chen, Cristina T. Dodge, Thomas J. Ow, James A. Bankson, Jeffrey N. Myers, and Stephen Y. Lai

Correction: Microtubule Inhibitors: Differentiating Tubulin-Inhibiting Agents Based on Mechanisms of Action, Clinical Activity, and Resistance

ABOUT THE COVER

The CEACAM1 protein protects melanoma cells from cytotoxic lymphocytes in vitro via homophilic intercellular interactions. Immunohistochemistry of a human lymph node infiltrated with melanoma cells for CEACAM1 (brown pigmentation) and CD8 (pink pigmentation) showed that almost all CD8-positive lymphocytes in the tumor and its close vicinity were CEACAM1⁺, while most lymphocytes in other areas distant from tumor edge were mostly CEACAM1⁻. This strongly suggests that CEACAM1-mediated inhibition occurs in vivo and thus its blockade is a promising strategy for cancer immunotherapy. For details, see article by Ortenberg and colleagues on page 1300.